EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Efficacy of Dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric real-life study

Govoni Marco, Soncini Arianna, Cuda Domenico, Oretti Gabriele, Lazio Maria Silvia, Zambonini Giulia, Ugolini Sara, Herman Irene, Carpentiero Colarusso Celeste, Liaci Enrico, Pasanisi Enrico, Salsi Daria

European Archives of Oto-Rhino-Laryngology · 2025-08 · 282 (8) · 4097-4107

DOI: 10.1007/s00405-025-09540-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 12.07.2025. Verfasst von Govoni Marco und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology and Otoneurosurgery, University Hospital of Parma, Viale Antonio Gramsci, 14, Parma (PR), 43126, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Polyps, Rhinosinusitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with morbidity and impairment in quality of life. Lately, new biological drugs have been developed and approved for its treatment. Dupilumab was the first to be approved but long-term real-world results are still limited. METHODS: This is a real-life, multicenter observational study assessing the effectiveness of dupilumab in patients with CRSwNP with a follow-up from 3 to 24 months. We focused on nasal polyps score (NPS), quality of life (SNOT-22), olfactory function and blood eosinophils trend. Moreover, results were stratified by previous surgery, comorbidities, and blood eosinophils and IgE levels at baseline. RESULTS: We observed a significant decrease in NPS and SNOT-22 from baseline to all the follow-up sessions. Olfaction improved over time and a significant difference was observed between baseline and 12 and 18 months. At 12 months follow-up, NPS of patients who had undergone surgery was lower than NPS of naïve patients (p =.012). Surgery did not influence SNOT-22 or improvement of smell. Comorbidities did not affect the outcomes. Blood eosinophils increased from baseline, reaching a peak at 3 months and gradually decreasing to a value similar to baseline at 18 months. The level of blood eosinophils and total IgE at baseline did not influence the effect of the drug on NPS at 12 months. No major adverse events were observed. CONCLUSION: Dupilumab was proven to be effective in terms of reduction of dimension of nasal polyps, improvement of quality of life and olfaction and no major adverse events were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNasal PolypsRhinosinusitisAdultAgedFemaleHumansMaleMiddle AgedChronic DiseaseEosinophilsFollow-Up StudiesImmunoglobulin EQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

Biological drugCRSwNPChronic rhinosinusitisDupilumabNasal polyposisOlfaction

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabImmunoglobulin E

Autor:innen und Institutionen

  • Department of Otorhinolaryngology and Otoneurosurgery, University Hospital of Parma, Viale Antonio Gramsci, 14, Parma (PR), 43126, Italy.
  • Department of Otorhinolaryngology and Otoneurosurgery, University Hospital of Parma, Viale Antonio Gramsci, 14, Parma (PR), 43126, Italy. arianna.soncini@gmail.com.
  • Department of Medicine and Surgery, University of Parma, Viale Antonio Gramsci, 14, Parma (PR), 43126, Italy. arianna.soncini@gmail.com.
  • Department of Medicine and Surgery, University of Parma, Viale Antonio Gramsci, 14, Parma (PR), 43126, Italy.
  • Department of Otorhinolaryngology, Guglielmo da Saliceto Hospital, Via Taverna Giuseppe, 49, Piacenza (PC), 29121, Italy.

Zitieren

APA

Marco, G., Arianna, S., Domenico, C., Gabriele, O., Silvia, L. M., Giulia, Z., Sara, U., Irene, H., Celeste, C. C., Enrico, L., Enrico, P., & Daria, S. (2025). Efficacy of Dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric real-life study. European Archives of Oto-Rhino-Laryngology, 282(8), 4097-4107. https://doi.org/10.1007/s00405-025-09540-4

Vancouver

Marco G, Arianna S, Domenico C, Gabriele O, Silvia LM, Giulia Z, et al. Efficacy of Dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric real-life study. European Archives of Oto-Rhino-Laryngology. 2025;282(8):4097-4107. doi:10.1007/s00405-025-09540-4

BibTeX
@article{Marco2025,
  author = {Marco, Govoni and Arianna, Soncini and Domenico, Cuda and Gabriele, Oretti and Silvia, Lazio Maria and Giulia, Zambonini and Sara, Ugolini and Irene, Herman and Celeste, Carpentiero Colarusso and Enrico, Liaci and Enrico, Pasanisi and Daria, Salsi},
  title = {Efficacy of Dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric real-life study},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2025},
  volume = {282},
  number = {8},
  pages = {4097--4107},
  doi = {10.1007/s00405-025-09540-4}
}
Kostenlos starten →